Polypill eligibility and equivalent intake in a Swiss population-based study

Abstract The polypill has been advocated for cardiovascular disease (CVD) management. The fraction of the population who could benefit from the polypill in Switzerland is unknown. Assess (1) the prevalence of subjects (a) eligible for the polypill and (b) already taking a polypill equivalent; and (2...

Full description

Bibliographic Details
Main Authors: Julien Castioni, Nazanin Abolhassani, Peter Vollenweider, Gérard Waeber, Pedro Marques-Vidal
Format: Article
Language:English
Published: Nature Publishing Group 2021-03-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-84455-8